((Jamie Lee, PharmD))
The administration schedule for VYXEOS is different than the traditional 7+3 regimen and allows for less infusion time.
For the first cycle, VYXEOS induction is administered on Days 1, 3, and 5 for 90 minutes and consolidation is administered on Days 1 and 3 for 90 minutes.
A full course of VYXEOS treatment consists of up to 2 cycles of induction and up to 2 cycles of consolidation.
In the Phase 3 trial, most patients received induction with VYXEOS in the inpatient setting.
Fifty-one percent of patients received consolidation in the outpatient setting.
In my institution we have experience administering Vyxeos outpatient for induction and consolidation.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION